Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8133145 | 0.84 | CYP3A4 (0.59) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL12442612 | 0.83 | CYP3A4 (0.58) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL31087166 | 0.83 | CYP3A4 (0.58) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL28254880 | 0.81 | CYP3A4 (0.56) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL4820083 | 0.80 | CYP3A4 (0.55) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL27490427 | 0.80 | GAA (0.61) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL13772554 | 0.80 | CYP3A4 (0.63) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| SCHEMBL31158548 | 0.80 | NPC1 (0.54) | SMN1; SMN2CYP3A4CYP2C9ALDH1A1HPGD | |
| SCHEMBL3758802 | 0.78 | CYP3A4 (0.52) | CYP3A4HSD17B10USP2CYP2C9CASP1 | |
| Ethylene SCHEMBL8381698 | 0.78 | GAA (0.58) | CYP3A4HSD17B10USP2CYP2C9CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | claimed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | claimed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | claimed |
| EP-4110766-A1 | PESTICIDALLY ACTIVE DIAZINE-BISAMIDE COMPOUNDS | Syngenta Crop Protection AG (CH) | 2023-01-04 | — | — | EP | disclosed |
| US-20110177612-A1 | Human G Protein-Coupled Receptors and Modulators Thereof for the Treatment of Metabolic-Related Disorders | ARENA PHARMACEUTICALS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-7829298-B2 | Human G protein-coupled receptors for metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | ARENA PHARMACEUTICALS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1811996-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | Arena Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006052569-A1 | COMPOSITIONS FOR TREATING FLUSHING AND LIPID-ASSOCIATED DISORDERS COMPRISING NIACIN RECEPTOR PARTIAL AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-07-14 | — | — | US | disclosed |
| US-6902902-B2 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | ARENA PHARMACEUTICALS, INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154029-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885CYP3A4 4617/4885HSD17B10 1211/4885 |
| US-20070079392-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885CYP3A4 4617/4885HSD17B10 1211/4885 |
| US-20080139628-A1 | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists | FFAR1, FFAR2, FFAR3 | SMN1; SMN2 4460/4885CYP3A4 603/4885HSD17B10 710/4885 |
| US-20050004178-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885CYP3A4 4617/4885HSD17B10 1211/4885 |
| US-20040142377-A1 | Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders | GPR119, ADIPOR2, GCGR | SMN1; SMN2 1613/4885CYP3A4 4617/4885HSD17B10 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.